SCHEMBL1720311

SCHEMBL1720311

O=C1c2ccccc2C(=O)N1[C@@H]1C[C@@H]1c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 3/20 0.56
KDM1A O60341 6/20 0.41
MAOB P27338 8/20 0.41
MAOA P21397 7/20 0.41
CYP2C19 P33261 4/20 0.41
HTR2C P28335 4/20 0.41
CYP2B6 P20813 3/20 0.41
CYP1A2 P05177 3/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41
TAAR1 Q96RJ0 2/20 0.41
LMNA P02545 1/20 0.41
CYP3A4 P08684 1/20 0.41
HTR1A P08908 1/20 0.41
ADRA2A P08913 1/20 0.41
CYP2A6 P11509 1/20 0.41
SLC6A2 P23975 1/20 0.41
ADRA1A P35348 1/20 0.41
DRD3 P35462 1/20 0.41
SLC6A3 Q01959 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1720667 1.00 SMO (0.56) SMOKDM1AMAOBMAOACYP2C19
SCHEMBL15200670 0.86 SMO (0.46) SMOKDM1AMAOBHTR2CSLC6A2
SCHEMBL19609316 0.86 SMO (0.46) SMOKDM1AMAOBHTR2CSLC6A2
SCHEMBL30567560 0.86 SMO (0.46) SMOKDM1AMAOBHTR2CSLC6A2
SCHEMBL16355425 0.86 SMO (0.46) SMOKDM1AMAOBHTR2CSLC6A2
SCHEMBL15200669 0.86 SMO (0.46) SMOKDM1AMAOBHTR2CSLC6A2
SCHEMBL19609727 0.86 SMO (0.46) SMOKDM1AMAOBHTR2CSLC6A2
SCHEMBL30567561 0.86 SMO (0.46) SMOKDM1AMAOBHTR2CSLC6A2
SCHEMBL22465825 0.86 SMO (0.46) SMOKDM1AMAOBHTR2CSLC6A2
SCHEMBL12860003 0.86 SMO (0.46) SMOKDM1AMAOBCYP2C19HTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1819708-B1 SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES BOEHRINGER INGELHEIM INT (DE) 2012-01-11 EP disclosed
US-7648988-B2 Substituted pteridines for the treatment of inflammatory diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH 2010-01-19 US disclosed
US-20080153833-A1 Substituted pteridines for the treatment of inflammatory diseases DOLLINGER HORST 2008-06-26 US disclosed
EP-1819708-A2 SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES Boehringer Ingelheim International GmbH (DE) 2007-08-22 EP disclosed
WO-2006058868-A2 SUBSTITUTED PTERIDINES FOR TREATING INFLAMMATORY DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-06-08 WO disclosed
US-20060116370-A1 Substituted pteridines for the treatment of inflammatory diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060116370-A1 Substituted pteridines for the treatment of inflammatory diseases LTC4S, TLR5, LTB4R2 SMO 3262/4885KDM1A 3906/4885MAOB 716/4885
US-20080153833-A1 Substituted pteridines for the treatment of inflammatory diseases LTC4S, TLR5, LTB4R2 SMO 3262/4885KDM1A 3906/4885MAOB 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.